CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

Clay H. Holdsworth, Ramsey D Badawi, Judith B. Manola, Marie F. Kijewski, David A. Israel, George D. Demetri, Annick D. Van Den Abbeele

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

OBJECTIVE: We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). SUBJECTS AND METHODS: Sixty-three patients enrolled in a multicenter trial evaluating imatinib mesylate therapy for advanced GIST underwent FDG PET at baseline and 1 month after initiation of treatment. Of these 63 patients, 58 underwent concomitant CT. Time-to-treatment failure (TTF) was used as the outcome measure. Patients were followed up over a range of 23.7 to 37 months (median, 31.7 months). The predictive power of change in CT bidimensional measurements, change in PET SUVmax, and PET SUVmax at 1 month after initiation of treatment were determined, optimized, and compared. The effectiveness of combining metrics was also evaluated. RESULTS: Both a threshold PET SUVmax value of 2.5 at 1 month (p = 0.04) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for partial response on FDG PET (25% reduction in PET SUVmax) at 1 month (p = 0.004) were predictive of prolonged treatment success. The Southwest Oncology Group (SWOG) criteria for partial response ((3) 50% reduction in CT bidimensional measurements) at 1 month were not predictive (p = 0.55) of TTF. Optimizing metrics improved results performance. An optimized PET SUVmax threshold of 3.4 (p = 0.00002), a reduction in the SUVmax of 40% (p = 0.002), and an optimized CT bidimensional measurement threshold--that is, no growth from baseline to 1 month (p = 0.00005)--outperformed the existing standards (i.e., EORTC and SWOG criteria). Combinations of metrics did not improve performance. CONCLUSION: The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.

Original languageEnglish (US)
JournalAJR. American journal of roentgenology
Volume189
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Treatment Failure
Therapeutics
Fluorodeoxyglucose F18
Growth
Imatinib Mesylate
Positron Emission Tomography Computed Tomography
Research
Multicenter Studies
Neoplasms
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CT and PET : early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. / Holdsworth, Clay H.; Badawi, Ramsey D; Manola, Judith B.; Kijewski, Marie F.; Israel, David A.; Demetri, George D.; Van Den Abbeele, Annick D.

In: AJR. American journal of roentgenology, Vol. 189, No. 6, 12.2007.

Research output: Contribution to journalArticle

Holdsworth, Clay H. ; Badawi, Ramsey D ; Manola, Judith B. ; Kijewski, Marie F. ; Israel, David A. ; Demetri, George D. ; Van Den Abbeele, Annick D. / CT and PET : early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. In: AJR. American journal of roentgenology. 2007 ; Vol. 189, No. 6.
@article{611e3633ca484211ac10dafc9bbde4b0,
title = "CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.",
abstract = "OBJECTIVE: We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). SUBJECTS AND METHODS: Sixty-three patients enrolled in a multicenter trial evaluating imatinib mesylate therapy for advanced GIST underwent FDG PET at baseline and 1 month after initiation of treatment. Of these 63 patients, 58 underwent concomitant CT. Time-to-treatment failure (TTF) was used as the outcome measure. Patients were followed up over a range of 23.7 to 37 months (median, 31.7 months). The predictive power of change in CT bidimensional measurements, change in PET SUVmax, and PET SUVmax at 1 month after initiation of treatment were determined, optimized, and compared. The effectiveness of combining metrics was also evaluated. RESULTS: Both a threshold PET SUVmax value of 2.5 at 1 month (p = 0.04) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for partial response on FDG PET (25{\%} reduction in PET SUVmax) at 1 month (p = 0.004) were predictive of prolonged treatment success. The Southwest Oncology Group (SWOG) criteria for partial response ((3) 50{\%} reduction in CT bidimensional measurements) at 1 month were not predictive (p = 0.55) of TTF. Optimizing metrics improved results performance. An optimized PET SUVmax threshold of 3.4 (p = 0.00002), a reduction in the SUVmax of 40{\%} (p = 0.002), and an optimized CT bidimensional measurement threshold--that is, no growth from baseline to 1 month (p = 0.00005)--outperformed the existing standards (i.e., EORTC and SWOG criteria). Combinations of metrics did not improve performance. CONCLUSION: The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.",
author = "Holdsworth, {Clay H.} and Badawi, {Ramsey D} and Manola, {Judith B.} and Kijewski, {Marie F.} and Israel, {David A.} and Demetri, {George D.} and {Van Den Abbeele}, {Annick D.}",
year = "2007",
month = "12",
doi = "10.2214/AJR.07.2496",
language = "English (US)",
volume = "189",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

TY - JOUR

T1 - CT and PET

T2 - early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

AU - Holdsworth, Clay H.

AU - Badawi, Ramsey D

AU - Manola, Judith B.

AU - Kijewski, Marie F.

AU - Israel, David A.

AU - Demetri, George D.

AU - Van Den Abbeele, Annick D.

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVE: We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). SUBJECTS AND METHODS: Sixty-three patients enrolled in a multicenter trial evaluating imatinib mesylate therapy for advanced GIST underwent FDG PET at baseline and 1 month after initiation of treatment. Of these 63 patients, 58 underwent concomitant CT. Time-to-treatment failure (TTF) was used as the outcome measure. Patients were followed up over a range of 23.7 to 37 months (median, 31.7 months). The predictive power of change in CT bidimensional measurements, change in PET SUVmax, and PET SUVmax at 1 month after initiation of treatment were determined, optimized, and compared. The effectiveness of combining metrics was also evaluated. RESULTS: Both a threshold PET SUVmax value of 2.5 at 1 month (p = 0.04) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for partial response on FDG PET (25% reduction in PET SUVmax) at 1 month (p = 0.004) were predictive of prolonged treatment success. The Southwest Oncology Group (SWOG) criteria for partial response ((3) 50% reduction in CT bidimensional measurements) at 1 month were not predictive (p = 0.55) of TTF. Optimizing metrics improved results performance. An optimized PET SUVmax threshold of 3.4 (p = 0.00002), a reduction in the SUVmax of 40% (p = 0.002), and an optimized CT bidimensional measurement threshold--that is, no growth from baseline to 1 month (p = 0.00005)--outperformed the existing standards (i.e., EORTC and SWOG criteria). Combinations of metrics did not improve performance. CONCLUSION: The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.

AB - OBJECTIVE: We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). SUBJECTS AND METHODS: Sixty-three patients enrolled in a multicenter trial evaluating imatinib mesylate therapy for advanced GIST underwent FDG PET at baseline and 1 month after initiation of treatment. Of these 63 patients, 58 underwent concomitant CT. Time-to-treatment failure (TTF) was used as the outcome measure. Patients were followed up over a range of 23.7 to 37 months (median, 31.7 months). The predictive power of change in CT bidimensional measurements, change in PET SUVmax, and PET SUVmax at 1 month after initiation of treatment were determined, optimized, and compared. The effectiveness of combining metrics was also evaluated. RESULTS: Both a threshold PET SUVmax value of 2.5 at 1 month (p = 0.04) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for partial response on FDG PET (25% reduction in PET SUVmax) at 1 month (p = 0.004) were predictive of prolonged treatment success. The Southwest Oncology Group (SWOG) criteria for partial response ((3) 50% reduction in CT bidimensional measurements) at 1 month were not predictive (p = 0.55) of TTF. Optimizing metrics improved results performance. An optimized PET SUVmax threshold of 3.4 (p = 0.00002), a reduction in the SUVmax of 40% (p = 0.002), and an optimized CT bidimensional measurement threshold--that is, no growth from baseline to 1 month (p = 0.00005)--outperformed the existing standards (i.e., EORTC and SWOG criteria). Combinations of metrics did not improve performance. CONCLUSION: The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.

UR - http://www.scopus.com/inward/record.url?scp=38449102069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449102069&partnerID=8YFLogxK

U2 - 10.2214/AJR.07.2496

DO - 10.2214/AJR.07.2496

M3 - Article

C2 - 18029844

AN - SCOPUS:36448965201

VL - 189

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 6

ER -